Cargando…

Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir

The effect of treatment with favipiravir, an antiviral purine nucleoside analog, for coronavirus disease 2019 (COVID-19) on the production and duration of neutralizing antibodies for SARS-CoV-2 was explored. There were 17 age-, gender-, and body mass index-matched pairs of favipiravir treated versus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shinada, Kanako, Sato, Takashi, Moriyama, Saya, Adachi, Yu, Shinoda, Masahiro, Ota, Shinichiro, Morikawa, Miwa, Mineshita, Masamichi, Matsumura, Takayuki, Takahashi, Yoshimasa, Shinkai, Masaharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024984/ https://www.ncbi.nlm.nih.gov/pubmed/35458400 http://dx.doi.org/10.3390/v14040670

Ejemplares similares

Two Cases of Severe COVID-19 Pneumonia Effectively Treated with Extracorporeal Membrane Oxygenation in Addition to Favipiravir and Corticosteroid
por: Shinoda, Masahiro, et al.
Publicado: (2021)

A case of COVID-19 pneumonia successfully treated with favipiravir (Avigan) in which serum SARS-CoV-2 RNA detected by LAMP method was clinically useful
por: Hirouchi, Takatomo, et al.
Publicado: (2021)

High Fever, Wide Distribution of Viral Pneumonia, and Pleural Effusion are More Critical Findings at the First Visit in Predicting the Prognosis of COVID-19: A Single Center, retrospective, Propensity Score-Matched Case–Control Study
por: Shinoda, Masahiro, et al.
Publicado: (2023)

Clinical Features of 154 COVID-19 Patients and the Parameters for the Effective Detection of Pneumonia at the Time of the Initial Diagnosis in Japan
por: Morikawa, Miwa, et al.
Publicado: (2020)

An intrathoracic giant tumour and vanishing lung cyst after tumour resection
por: Nishimura, Masashi, et al.
Publicado: (2021)

Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine
por: Takano, Tomohiro, et al.
Publicado: (2022)

Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants
por: Moriyama, Saya, et al.
Publicado: (2021)

Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain
por: Takano, Tomohiro, et al.
Publicado: (2023)

SARS-CoV-2 Omicron-neutralizing memory B-cells are elicited by two doses of BNT162b2 mRNA vaccine
por: Kotaki, Ryutaro, et al.
Publicado: (2022)

SARS-CoV-2-specific CD4(+) T cell longevity correlates with Th17-like phenotype
por: Terahara, Kazutaka, et al.
Publicado: (2022)

CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes
por: Onodera, Taishi, et al.
Publicado: (2023)

Possibility of underestimation of COVID-19 prevalence by PCR and serological tests
por: Ota, Shinichiro, et al.
Publicado: (2022)

Detection of silent infection of severe acute respiratory syndrome coronavirus 2 by serological tests
por: Nishimura, Masashi, et al.
Publicado: (2022)

Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses
por: Shinnakasu, Ryo, et al.
Publicado: (2021)

Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization
por: Miyamoto, Sho, et al.
Publicado: (2023)

Acute eosinophilic pneumonia caused by camostat mesilate: The first case report
por: Ota, Shinichiro, et al.
Publicado: (2016)

Clinical Significance of Serum Hemeoxygenase-1 as a New Biomarker for the Patients with Interstitial Pneumonia
por: Murohashi, Kota, et al.
Publicado: (2018)

Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
por: Miyamoto, Sho, et al.
Publicado: (2022)

A case of reinfection with a different variant of SARS-CoV-2: case report
por: Shimada, Nagashige, et al.
Publicado: (2023)

COVID‐19 pneumonia and an indelible ground‐glass nodule
por: Yamanaka, Sumitaka, et al.
Publicado: (2021)

Evaluation of Droplet Countermeasures by a Particle Visualization System in Simulated Bronchoscopy
por: Morikawa, Kei, et al.
Publicado: (2021)

Preliminary Results of NGS Gene Panel Test Using NSCLC Sputum Cytology and Therapeutic Effect Using Corresponding Molecular-Targeted Drugs
por: Morikawa, Kei, et al.
Publicado: (2022)

Pre-treatment bronchoscopic evaluation in a case of relapsing polychondrits
por: Kumagai, Kosumi, et al.
Publicado: (2023)

Favipiravir Inhibits Hepatitis A Virus Infection in Human Hepatocytes
por: Sasaki-Tanaka, Reina, et al.
Publicado: (2022)

Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial
por: Shinkai, Masaharu, et al.
Publicado: (2021)

Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients
por: Takeshita, Masaru, et al.
Publicado: (2022)

Humoral immunity for durable control of SARS-CoV-2 and its variants
por: Kotaki, Ryutaro, et al.
Publicado: (2023)

Severe tracheal stenosis with tracheopathia osteoplastica-like changes due to traumatic blunt injury
por: Kakinuma, Kazutaka, et al.
Publicado: (2014)

Drastic healing process after pembrolizumab monotherapy in a case of advanced squamous cell carcinoma with severe bronchial stenosis observed over a two‐year period using continuous bronchoscopy: A case report
por: Morikawa, Kei, et al.
Publicado: (2020)

A case of advanced adenocarcinoma genetically confirmed with EGFR/BRAF co-mutation in both primary and metastatic lesions
por: Morikawa, Kei, et al.
Publicado: (2021)

Detection of a pinhole‐sized bronchoesophageal fistula under bronchoscopic autofluorescence imaging
por: Morikawa, Kei, et al.
Publicado: (2021)

Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan
por: Takeshita, Masaru, et al.
Publicado: (2021)

ICU admission and favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Esophagectasis Related to Rivastigmine
por: Sasaki, Osamu, et al.
Publicado: (2019)

Asymptomatic ceftriaxone‐associated pseudolithiasis
por: Sasaki, Osamu, et al.
Publicado: (2019)

Solithromycin inhibits IL-13-induced goblet cell hyperplasia and MUC5AC, CLCA1, and ANO1 in human bronchial epithelial cells
por: Kimura, Yasuhiro, et al.
Publicado: (2023)

Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non‐small cell lung cancer
por: Kakinuma, Kazutaka, et al.
Publicado: (2017)

A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer
por: Tsunoda, Akihito, et al.
Publicado: (2019)

Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer
por: Oyama, Baku, et al.
Publicado: (2021)

Equal Neutralization Potency of Antibodies Raised against Abrin Subunits
por: Gal, Yoav, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7efl1tq4ulcs3t2p4gqhbm94rk